Latest News - Regeneron Pharmaceuticals
Top Corporates Hub
Regeneron Pharmaceuticals
Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Lowers Price Target to $769
07.07.2026 07:36
Truist Securities analyst Gregory Renza maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and lowers the price target from $778 to $769.
This Meta Platforms Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
07.07.2026 07:06
Top Wall Street analysts upgraded FSLR, META, WM, NET, and REGN stocks. Check out analyst ratings page for more details and opinions.
Benchmark Upgrades Regeneron Pharmaceuticals to Buy, Announces $185 Price Target
07.07.2026 06:37
Benchmark analyst Robert Wasserman upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) from Hold to Buy and announces $185 price target.
Dupilumab Achieves Record $11.9 Billion in Global Sales Amidst Continued Growth
03.07.2026 08:40
Dupilumab's growth is driven by its established market presence, new indications like COPD, broad multi-indication use, and strong clinical performance. Recent approvals and phase III trial successes, coupled with its diverse application across conditions, create substantial market opportunities and competitive advantages.Dublin, July 03, 2026 (GLOBE NEWSWIRE) -- The "Dupilumab Sales Forecast, and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering. Key Factors Drivi
Lilly and Regeneron amongst first incumbents to FDA’s fast-track facility scheme
30.06.2026 15:31
Seven pharma companies have been selected for the FDA PreCheck pilot – a framework intended to bolster the US drug supply chain.
Talawar Therapeutics to debut on Nasdaq with $285m as Dupixent challenger
30.06.2026 10:53
The newly formed biotech will use the funds to take its eczema bispecific, TALA-125, through to Phase IIb proof-of-concept trials.
Eli Lilly, Regeneron Join FDA Pilot Designed To Accelerate US Manufacturing Readiness
30.06.2026 10:17
FDA names seven companies to its PreCheck pilot to speed U.S. drug manufacturing reviews after receiving more than 80 applications.
RBC Capital Maintains a Sector Perform Rating on Regeneron (REGN) – Here’s Why
28.06.2026 14:01
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best non-tech stocks to buy according to analysts. RBC Capital maintained a Sector Perform rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on June 22, setting a $707 price target. However, the firm noted that AbbVie’s acquisition of Apogee Therapeutics, announced that morning, is a net negative for the company. […]
Here's Why You Should Add Kiniksa Stock to Your Portfolio Now
26.06.2026 14:34
KNSA's Arcalyst sales continue to grow as raised 2026 revenue guidance and an expanding IL-1 pipeline reinforce Kiniksa's growth strategy.
AbbVie’s $10.9 Billion Apogee Therapeutics Buyout Protects Its Immunology Crown
22.06.2026 12:23
AbbVie will acquire the clinical-stage biotech’s pipeline of candidates for inflammatory and immunological diseases.
Questex’s DPHARM Announces Senior Leadership and Keynotes for the 16th Annual Conference
22.06.2026 12:00
BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- DPHARM, the leading innovation event for clinical trial operation executives, announces the 16th annual conference agenda including its senior leadership and keynotes. DPHARM which is now part of Questex’s Fierce Life Sciences, takes place September 15-16, 2026, at the Sheraton Boston Hotel. The first line up of senior level clinical operation executives include: Jennifer Sheller, SVP, Head of Global Clinical Trial Operations, Global Clinical Development
Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)
22.06.2026 11:00
Cemdisiran could be the first siRNA approved for the treatment of gMG and only therapy to be offered subcutaneously with four times a year dosing FDA accepted NDA under Priority Review with a target action date in November 2026; European Commission decision anticipated in the second half of 2027 TARRYTOWN, N.Y., June 22, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA)
Is Sanofi (SNY) A Good Stock To Buy Now?
19.06.2026 14:56
Is SNY a good stock to buy? We came across a bullish thesis on Sanofi on r/ValueInvesting by stefanliemawan. In this article, we will summarize the bulls’ thesis on SNY. Sanofi’s share was trading at $42.38 as of June 18th. SNY’s trailing and forward P/E were 18.43 and 8.44 respectively according to Yahoo Finance. Sanofi engages in […]
Is CytomX (CTMX) One of the Best Growth Stocks Under $30 to Buy Now?
19.06.2026 07:00
CytomX Therapeutics Inc. (NASDAQ:CTMX) is one of the best growth stocks under $30 to buy now. On June 3, CytomX expanded its research collaboration with Regeneron to develop next-gen conditionally-activated bispecific cancer therapies. By combining CytomX’s PROBODY masking platform with Regeneron’s Veloci-Bi technology, the partnership aims to create treatments that remain inactive until reaching the […]
Regeneron Broadens Pipeline With Ebola Antibody Trials And Bispecific Cancer Bets
13.06.2026 03:10
World Health Organization prioritizes Regeneron’s maftivimab for clinical trials targeting Bundibugyo ebolavirus as part of the global Ebola emergency response. Regeneron Pharmaceuticals (NasdaqGS:REGN) expands its collaboration with CytomX to develop conditionally activated bispecific cancer therapies. For Regeneron Pharmaceuticals (NasdaqGS:REGN), these updates highlight the company’s activity in both infectious disease and oncology. The World Health Organization’s focus on maftivimab...
IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up
12.06.2026 13:48
Immuneering stock rises after dosing the first patient in a pivotal phase III study of atebimetinib plus mGnP for first-line metastatic pancreatic cancer.
REGN (NASDAQ:REGN) Presents a Classic Value Opportunity with Strong Fundamentals
12.06.2026 10:30
Regeneron Pharmaceuticals (REGN) shows strong value with a P/E of 13.4, solid financial health, and double-digit growth potential, making it a compelling pick for value investors.
Parabilis Medicines raises record $670 million in biotech IPO
10.06.2026 16:21
The Cambridge, Massachusetts-based biotech priced 33.5 million shares at $20 each, topping the $625 million raised by Kailera Therapeutics in April
Parabilis sets a record with a $670M biotech IPO
10.06.2026 11:06
The largest-ever new stock sale for a venture-backed biotech company extends a streak of large IPOs in 2026 that’s now resulted in 12 drug startups securing more than $4.1 billion combined.
Regeneron: 'Buy' Revenue Growth And Two Extensive Drug Development Opportunities
08.06.2026 02:48
Regeneron's EYLEA HD US sales surged 52% in Q1 2026, offsetting competitive pressures and patient switching within the EYLEA franchise. See why REGN is a Buy.